Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Regeneron (IT:1REGN)
MILAN:1REGN
Holding IT:1REGN?
Track your performance easily
See the Price Targets and Ratings of:
1REGN Analyst Ratings
Moderate Buy
16 Buy
5 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
1REGN Stock 12 Month Forecast
Average Price Target
€1,059.23
▲(55.63% Upside)
| Highest Price Target€1,254 | Average Price Target€1,059 | Lowest Price Target€545.15 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Jefferies
Reiterated
12/20/24
TD Cowen
Reiterated
12/20/24
Canaccord Genuity
Reiterated
12/19/24
Leerink Partners
Reiterated
12/16/24
Piper Sandler
Reiterated
12/10/24
Bank of America Securities
Initiated
12/10/24
Morgan Stanley
Assigned
12/06/24
Citi
Reiterated
11/25/24
RBC Capital
Reiterated
11/25/24
Bernstein
Reiterated
11/25/24
Wolfe Research
€1,109.59
Buy
63.03%
Upside
Initiated
11/14/24
Regeneron initiated with an Outperform at Wolfe ResearchRegeneron initiated with an Outperform at Wolfe Research
Oppenheimer
€964.87
Buy
41.77%
Upside
Assigned
11/06/24
Regeneron price target lowered to $1,000 from $1,150 at OppenheimerRegeneron price target lowered to $1,000 from $1,150 at Oppenheimer
Truist Financial
€1,097.05→€1,086.44
Buy
59.63%
Upside
Reiterated
11/05/24
Analysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Regeneron (REGN)
Evercore ISI
€1,128.89
Buy
65.87%
Upside
Assigned
11/01/24
Regeneron Pharma (REGN) PT Lowered to $1,170 at Evercore ISIEvercore ISI analyst Cory Kasimov lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,170.00 (from $1,175.00) while maintaining a Outperform rating.
UBS
€1,207.05→€1,090.3
Buy
60.20%
Upside
Reiterated
11/01/24
Regeneron Pharma (REGN) PT Lowered to $1,130 at UBSUBS analyst Colin Bristow lowered the price target on Regeneron Pharma (NASDAQ: REGN) to $1,130.00 (from $1,251.00) while maintaining a Buy rating.
Best Analysts Covering Regeneron
Which Analyst Should I Follow If I Want to Buy IT:1REGN and Sell After:
1 Month
xxx
Success Rate
9/15 ratings generated profit
Average Return
+0.57%
reiterated a xxx
rating 2 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +0.57% per trade.
3 Months
xxx
Success Rate
13/22 ratings generated profit
Average Return
+0.83%
assigned a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 59.09% of your transactions generating a profit, with an average return of +0.83% per trade.
1 Year
Success Rate
29/42 ratings generated profit
Average Return
+17.60%
reiterated a buy rating 12 days ago
Copying Christopher Raymond's trades and holding each position for 1 Year would result in 69.05% of your transactions generating a profit, with an average return of +17.60% per trade.
2 Years
xxx
Success Rate
24/42 ratings generated profit
Average Return
+21.34%
reiterated a xxx
rating 12 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 57.14% of your transactions generating a profit, with an average return of +21.34% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
1REGN Analyst Recommendation Trends
Rating
Aug 24
Sep 24
Oct 24
Nov 24
Dec 24
Strong Buy
0
0
1
2
7
Buy
43
51
57
53
32
Hold
3
6
8
10
8
Sell
0
1
1
2
2
Strong Sell
0
0
0
0
0
total
46
58
67
67
49
Each month's total comprises the sum of three months' worth of ratings.
1REGN Financial Forecast
1REGN Stock Forecast FAQ
What is IT:1REGN’s average 12-month price target, according to analysts?
Based on analyst ratings, Regeneron’s 12-month average price target is €1,059.23.
What is IT:1REGN’s upside potential, based on the analysts’ average price target?
Regeneron has 55.63% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Regeneron a Buy, Sell or Hold?
Regeneron has a consensus rating of Moderate Buy, which is based on 16 buy ratings, 5 hold ratings and 1 sell ratings.
What is Regeneron’s share price target?
The average share price target for Regeneron is €1,059.23. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €1,254.32 ,and the lowest forecast is €545.15. The average share price target represents 55.63% Increase from the current price of €680.6.
The highest analyst share price target is €1,254.32 ,and the lowest forecast is €545.15. The average share price target represents 55.63% Increase from the current price of €680.6.
What do analysts say about Regeneron?
Regeneron’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.
How can I buy shares of Regeneron?
To buy shares of IT:1REGN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.